CN1870995A - 使用埃坡霉素的癌症治疗 - Google Patents

使用埃坡霉素的癌症治疗 Download PDF

Info

Publication number
CN1870995A
CN1870995A CNA2004800313316A CN200480031331A CN1870995A CN 1870995 A CN1870995 A CN 1870995A CN A2004800313316 A CNA2004800313316 A CN A2004800313316A CN 200480031331 A CN200480031331 A CN 200480031331A CN 1870995 A CN1870995 A CN 1870995A
Authority
CN
China
Prior art keywords
purposes
treatment
proliferative disease
epothilones
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800313316A
Other languages
English (en)
Chinese (zh)
Inventor
C·达利
P·M·J·姆谢里
S-M·马伊拉
田中伦明
M·瓦特曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1870995A publication Critical patent/CN1870995A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CNA2004800313316A 2003-09-02 2004-09-01 使用埃坡霉素的癌症治疗 Pending CN1870995A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49954803P 2003-09-02 2003-09-02
US60/499,548 2003-09-02

Publications (1)

Publication Number Publication Date
CN1870995A true CN1870995A (zh) 2006-11-29

Family

ID=34272839

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800313316A Pending CN1870995A (zh) 2003-09-02 2004-09-01 使用埃坡霉素的癌症治疗

Country Status (9)

Country Link
US (2) US20060235059A1 (https=)
EP (1) EP1663214A1 (https=)
JP (1) JP2007504259A (https=)
CN (1) CN1870995A (https=)
AU (1) AU2004268377B2 (https=)
BR (1) BRPI0414043A (https=)
CA (1) CA2537057A1 (https=)
MX (1) MXPA06002393A (https=)
WO (1) WO2005020989A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
CN100384419C (zh) * 2005-12-02 2008-04-30 菏泽睿鹰制药集团有限公司 一种埃坡霉素缓释植入组合物及应用
EA020954B1 (ru) 2008-06-16 2015-03-31 Бинд Терапьютикс, Инк. Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
US8563041B2 (en) 2008-12-12 2013-10-22 Bind Therapeutics, Inc. Therapeutic particles suitable for parenteral administration and methods of making and using same
JP2012512175A (ja) 2008-12-15 2012-05-31 バインド バイオサイエンシズ インコーポレイテッド 治療薬を徐放するための長時間循環性ナノ粒子
DK2509634T3 (en) 2009-12-11 2019-04-23 Pfizer Stable formulations for lyophilization of therapeutic particles
EP2515942B1 (en) 2009-12-15 2020-02-12 Pfizer Inc. Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers
WO2011084521A2 (en) * 2009-12-15 2011-07-14 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same
WO2014043618A1 (en) 2012-09-17 2014-03-20 Bind Therapeutics, Inc. Process for preparing therapeutic nanoparticles
PE20170312A1 (es) 2014-03-14 2017-03-30 Pfizer Nanoparticulas terapeuticas que comprenden un agente terapeutico, y metodos para su elaboracion y uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820269A (en) * 1983-03-07 1989-04-11 Vanderbilt University Mixer apparatus for controlling intravenous drug infusion
US5968972A (en) * 1995-10-26 1999-10-19 Baker Norton Pharmaceuticals, Inc. Method for increasing the oral bioactivity of pharmaceutical agents
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
ES2304240T3 (es) * 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
MXPA04006822A (es) * 2002-01-14 2004-12-08 Novartis Ag Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1503756B1 (en) * 2002-05-01 2009-08-12 Novartis AG Epothilone derivative for the treatment of hepatoma and other cancer diseases
CN101389334A (zh) * 2002-05-20 2009-03-18 高山生物科学股份有限公司 埃坡霉素d的给药方法
BR0313198A (pt) * 2002-08-02 2005-07-12 Novartis Ag Derivados de epotilona
BR0317150A (pt) * 2002-12-09 2005-11-01 Novartis Ag Estabilizadores de microtúbulos em stents para o tratamento de estenose
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas

Also Published As

Publication number Publication date
US20060235059A1 (en) 2006-10-19
MXPA06002393A (es) 2006-06-20
EP1663214A1 (en) 2006-06-07
JP2007504259A (ja) 2007-03-01
AU2004268377B2 (en) 2008-06-26
CA2537057A1 (en) 2005-03-10
US20090069394A1 (en) 2009-03-12
BRPI0414043A (pt) 2006-10-24
WO2005020989A1 (en) 2005-03-10
AU2004268377A1 (en) 2005-03-10

Similar Documents

Publication Publication Date Title
US6635666B2 (en) Cancer treatment with epothilones
US20090069394A1 (en) Cancer treatment with epothilones
CN104507479B (zh) 通过联合治疗的半胱天冬酶‑3酶原激活
CN1679559A (zh) 癌症的治疗
CN1774253A (zh) 用环氧丙酯酮衍生物治疗顽固性肿瘤
CN101065127A (zh) 包含埃博霉素和蛋白酪氨酸激酶抑制剂的组合产品及其药物用途
CN1547471A (zh) 含有combretastatin和抗癌剂的复合药物
CN1361693A (zh) 1,4－苯并硫氮杂∴衍生物作为抗癌药抗性克服用药物的用途
CN1301996C (zh) 喜树碱和不饱和脂肪酸的新的抗癌共轭体
CN1575168A (zh) 包含选择性环加氧酶－2抑制剂的组合
CN101065129B (zh) 治疗癌症的n-(3-甲氧基-5-甲基吡嗪-2-基)-2-(4-[1，3，4-噁二唑-2-基]苯基)吡啶-3-磺酰胺和抗有丝分裂剂的组合
JP2009513486A (ja) エポチロンでの癌処置
RU2242229C2 (ru) Применение эпотилонов для лечения рака
AU2003202508B2 (en) Use of epothilones for the treatment of cancer
CN1299773C (zh) 一种抗癌药物组合物
CN1694691A (zh) 用蒽环类和紫杉烷类治疗转移性乳癌
CN1204962A (zh) 含2,2'－二－1h－吡咯化合物的协同免疫抑制组合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20061129